🇺🇸 US OMUFA FY2027 first instalment due; CMO fee up about 149%
1 Oct · United States · Confidence: Official text
What happens
The US Food and Drug Administration (FDA) published the FY2027 OTC Monograph Drug User Fee (OMUFA) rates on 29 July 2026: USD 47,891 for monograph drug facilities (MDF) and USD 31,927 for contract manufacturing organisations (CMO), about 149% higher than in FY2026 (FY2026 was an unusually low point following a one-off statutory reserve adjustment). The payment date moves from June to October, with two equal instalments due on 1 October 2026 and 1 February 2027.
What to do
Contract manufacturers producing OTC monograph drugs for US brands (e.g. acne products containing salicylic acid or benzoyl peroxide, and sunscreens) must pay the official CMO fee of USD 31,927, with the first half (USD 15,963.50) due on 1 October 2026. The fee should be factored into the cost of US OTC business. Non-OTC product lines are not affected.
Source
FDA OMUFA
Pick your category — get recalls & regulation alerts weekly
Leave your email and the category you make: each week we tell you what was recalled or noticed in the EU and US, which deadlines are close, and who just raised money. Or use RSS. Free; unsubscribe anytime.
- EU recalls and US Prop 65 notices in your category
- Upcoming regulatory deadlines
- Opportunities filtered for your role